Literature DB >> 28530443

Association of Single-Nucleotide Polymorphism in the Hepcidin Promoter Gene with Susceptibility to Extrapulmonary Tuberculosis.

Li Liang1, Huijuan Liu2, Jun Yue1, Li-Rong Liu1, Min Han1, Liu-Lin Luo1, Yan-Lin Zhao3, Heping Xiao1.   

Abstract

BACKGROUND: Hepcidin is a 25-amino acid peptide produced by the liver in response to inflammation and iron overload. It is encoded by the hepcidin antimicrobial peptide (HAMP) gene and plays a key role in innate immunity. Previous studies have reported that a -582 A>G polymorphism in the HAMP promoter (HAMP-P) affects hepcidin expression, causing susceptibility to various bacterial and viral pathogens. However, it is not known whether the HAMP-P -582 A>G polymorphism is associated with tuberculosis (TB) susceptibility. AIMS: The objective of the current study was to examine the relationship between the HAMP-P -582 A>G polymorphism and TB susceptibility in a Chinese Han population.
METHODS: Han Chinese subjects examined included 500 pulmonary TB, 386 extrapulmonary TB, and 600 healthy control subjects. We analyzed correlations between the hepcidin promoter -582 A>G polymorphism and disease susceptibility and then examined the regulatory effects of the -582 A>G variant on hepcidin production in CD14+ monocyte cultures stimulated with lipoarabinomannan derived from Mycobacterium tuberculosis.
RESULTS: Our findings indicate that the HAMP-P -582 A>G polymorphism (rs10421768) is associated with susceptibility to extrapulmonary TB, but not pulmonary TB. CD14+ monocytes from individuals with the rs10421768 GG genotype secreted significantly less hepcidin in response to M. tuberculosis lipoarabinomannan compared with cells from individuals with either the AA or AG genotypes.
CONCLUSIONS: The G allele of the HAMP-P -582 A>G gene may play a critical role in TB susceptibility.

Entities:  

Keywords:  extrapulmonary tuberculosis; hepcidin antimicrobial peptide; pulmonary tuberculosis; susceptibility; tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 28530443     DOI: 10.1089/gtmb.2016.0300

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  5 in total

1.  Hepcidin (rs10421768), Transferrin (rs3811647, rs1049296) and Transferrin Receptor 2 (rs7385804) Gene Polymorphism Might Be Associated with the Origin of Multiple Sclerosis.

Authors:  Laura Stachowska; Dorota Koziarska; Beata Karakiewicz; Artur Kotwas; Anna Knyszyńska; Marcin Folwarski; Karolina Dec; Ewa Stachowska; Viktoria Hawryłkowicz; Monika Kulaszyńska; Joanna Sołek-Pastuszka; Karolina Skonieczna-Żydecka
Journal:  Int J Environ Res Public Health       Date:  2022-06-04       Impact factor: 4.614

2.  Common Inflammation-Related Candidate Gene Variants and Acute Kidney Injury in 2647 Critically Ill Finnish Patients.

Authors:  Laura M Vilander; Suvi T Vaara; Mari A Kaunisto; Ville Pettilä; The Finnaki Study Group
Journal:  J Clin Med       Date:  2019-03-11       Impact factor: 4.241

3.  The Prevalence of Insomnia and the Link between Iron Metabolism Genes Polymorphisms, TF rs1049296 C>T, TF rs3811647 G>A, TFR rs7385804 A>C, HAMP rs10421768 A>G and Sleep Disorders in Polish Individuals with ASD.

Authors:  Karolina Skonieczna-Żydecka; Dominika Jamioł-Milc; Krzysztof Borecki; Ewa Stachowska; Paulina Zabielska; Magdalena Kamińska; Beata Karakiewicz
Journal:  Int J Environ Res Public Health       Date:  2020-01-08       Impact factor: 3.390

Review 4.  Lipoarabinomannan as a Point-of-Care Assay for Diagnosis of Tuberculosis: How Far Are We to Use It?

Authors:  Julio Flores; Juan Carlos Cancino; Leslie Chavez-Galan
Journal:  Front Microbiol       Date:  2021-04-15       Impact factor: 5.640

5.  Creatine kinase-(MB) and hepcidin as candidate biomarkers for early diagnosis of pulmonary tuberculosis: a proof-of-concept study in Lambaréné, Gabon.

Authors:  Paulin N Essone; Bayode R Adegbite; Marien J M Mbadinga; Armel V Mbouna; Fabrice Lotola-Mougeni; Ayodele Alabi; Jean R Edoa; Bertrand Lell; Abraham S Alabi; Ayola A Adegnika; Michael Ramharter; Joel F D Siawaya; Martin P Grobusch; Peter G Kremsner; Selidji T Agnandji
Journal:  Infection       Date:  2022-02-08       Impact factor: 7.455

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.